Defining the rectal dose constraint for permanent radioactive seed implantation of the prostate

Sylvester, 2003, Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: The Seattle experience, Int J Radiat Oncol Biol Phys, 57, 944, 10.1016/S0360-3016(03)00739-9 Grimm, 2001, 10-year biochemical (prostate-specific antigen) control of prostate cancer with I125 brachytherapy, Int J Radiat Oncol Biol Phys, 51, 31, 10.1016/S0360-3016(01)01601-7 D’Amico, 1998, Real time magnetic resonance image guided interstitial brachytherapy in the treatment of select patients with clinically localized prostate cancer, Int J Radiat Oncol Biol Phys, 42, 507, 10.1016/S0360-3016(98)00271-5 D’Amico, 2003, Comparing PSA outcome following radical prostatectomy or magnetic resonance image-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate, Urology, 62, 1063, 10.1016/S0090-4295(03)00772-6 Seo, 2001, Early symptoms and symptoms distress after standard ultrasound guided brachytherapy or MRI-guided brachytherapy in early stage prostate cancer, Proc Am Soc Clin Oncol, 20, 157b Albert, 2003, Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy, Cancer, 98, 949, 10.1002/cncr.11595 Gelblum, 2000, Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer, Int J Radiat Oncol Biol Phys, 48, 119, 10.1016/S0360-3016(00)00632-5 Hu, 1998, Clinical course of rectal bleeding following I125 prostate brachytherapy, Int J Radiat Oncol Biol Phys, 41, 263, 10.1016/S0360-3016(98)00080-7 Kang, 1995, Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy, Int J Radiat Oncol Biol Phys, 53, 99, 10.1016/S0360-3016(01)02811-5 Wallner, 1995, Dosimetric guidelines to minimize urethral and rectal morbidity following transperineal I125 prostate brachytherapy, Int J Radiat Oncol Biol Phys, 32, 465, 10.1016/0360-3016(94)00599-G Merrick, 1999, Rectal dosimetric analysis following prostate brachytherapy, Int J Radiat Oncol Biol Phys, 43, 1021, 10.1016/S0360-3016(98)00486-6 Snyder, 2001, Defining the risk of developing grade 2 proctitis following I125 prostate brachytherapy using a rectal dose-volume histogram analysis, Int J Radiat Oncol Biol Phys, 50, 335, 10.1016/S0360-3016(01)01442-0 Cox, 1995, Int J Radiat Oncol Biol Phys, 31, 1341, 10.1016/0360-3016(95)00060-C Han, 2001, Dosimetric and radiographic correlates to prostate brachytherapy-related rectal complications, Int. J. Cancer, 96, 372, 10.1002/ijc.1037 Waterman, 2003, Probability of late rectal morbidity in I125 prostate brachytherapy, Int J Radiat Oncol Biol Phys, 55, 342, 10.1016/S0360-3016(02)03934-2 Shah, 2006, Rectal toxicity profile after transperineal interstitial permanent prostate brachytherapy: Use of a comprehensive toxicity scoring system and identification of rectal dosimetric toxicity predictors, Int J Radiation Oncol Bio Phys, 64, 817, 10.1016/j.ijrobp.2005.08.042 Smith, 2001, Argon plasma coagulation for rectal bleeding after prostate brachytherapy, Int J Radiation Oncol Bio Phys, 51, 636, 10.1016/S0360-3016(01)01704-7 Venkatesh, 2002, Endoscopic therapy for radiation proctitis-induced hemorrhage in patients with prostatic carcinoma using argon plasma coagulator application, Surg Endosc, 16, 707, 10.1007/s00464-001-8164-0 D’Amico, 2006, A Prospective evaluation of rectal bleeding following dose escalated 3D conformal radiation therapy using an intrarectal balloon for prostate gland localization and immobilization, Urology, 67, 780, 10.1016/j.urology.2005.10.008